Plozasiran
High Risk Severe Hypertriglyceridemia (SHTG)
Arrowhead Pharmaceuticalsnucleic_acidPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the High Risk Severe Hypertriglyceridemia (SHTG) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fenofibrate Abbott | Phase 4 | BB |
Amprenavir Felizarta, Franco, M.D. | Phase 4 | BB |
Saffron Birjand University of Medical Sciences | Phase 4 | BB |
Lipitor The University of Western Australia | Phase 4 | BB |
ADVICOR COMPONENT NIACIN University of South Dakota | Phase 4 | BB |
View all 27 →
Same molecule, other indications
Plozasiran is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →